Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 May 2010
|
| In: |
Cardiovascular drugs and therapy
Year: 2010, Jahrgang: 24, Heft: 2, Pages: 175-180 |
| ISSN: | 1573-7241 |
| DOI: | 10.1007/s10557-010-6231-2 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10557-010-6231-2 Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887499/ 
|
| Verfasserangaben: | Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1751234096 | ||
| 003 | DE-627 | ||
| 005 | 20240412193302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210312s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10557-010-6231-2 |2 doi | |
| 035 | |a (DE-627)1751234096 | ||
| 035 | |a (DE-599)KXP1751234096 | ||
| 035 | |a (OCoLC)1341398756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hennerici, Michael G. |d 1948- |e VerfasserIn |0 (DE-588)11587545X |0 (DE-627)077527704 |0 (DE-576)290126444 |4 aut | |
| 245 | 1 | 0 | |a Rationale, design and population baseline characteristics of the PERFORM Vascular Project |b an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial |c Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul |
| 264 | 1 | |c 20 May 2010 | |
| 300 | |b Illustrationen | ||
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.03.2021 | ||
| 520 | |a Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients. - - Methods and results - The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006. - - Conclusions - The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs. | ||
| 700 | 1 | |a Bots, Michiel L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ford, Ian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Laurent, Stéphane |e VerfasserIn |4 aut | |
| 700 | 1 | |a Touboul, Pierre Jean |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular drugs and therapy |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1987 |g 24(2010), 2, Seite 175-180 |h Online-Ressource |w (DE-627)320429237 |w (DE-600)2003553-6 |w (DE-576)106890727 |x 1573-7241 |7 nnas |a Rationale, design and population baseline characteristics of the PERFORM Vascular Project an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial |
| 773 | 1 | 8 | |g volume:24 |g year:2010 |g number:2 |g pages:175-180 |g extent:6 |a Rationale, design and population baseline characteristics of the PERFORM Vascular Project an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10557-010-6231-2 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887499/ |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210312 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 11587545X |a Hennerici, Michael G. |m 11587545X:Hennerici, Michael G. |d 60000 |d 62700 |e 60000PH11587545X |e 62700PH11587545X |k 0/60000/ |k 1/60000/62700/ |p 1 |x j | ||
| 999 | |a KXP-PPN1751234096 |e 3885962381 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Rationale, design and population baseline characteristics of the PERFORM Vascular Project","title":"Rationale, design and population baseline characteristics of the PERFORM Vascular Project","subtitle":"an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial"}],"person":[{"display":"Hennerici, Michael G.","roleDisplay":"VerfasserIn","role":"aut","family":"Hennerici","given":"Michael G."},{"roleDisplay":"VerfasserIn","display":"Bots, Michiel L.","role":"aut","family":"Bots","given":"Michiel L."},{"family":"Ford","given":"Ian","display":"Ford, Ian","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Stéphane","family":"Laurent","role":"aut","display":"Laurent, Stéphane","roleDisplay":"VerfasserIn"},{"given":"Pierre Jean","family":"Touboul","role":"aut","display":"Touboul, Pierre Jean","roleDisplay":"VerfasserIn"}],"language":["eng"],"recId":"1751234096","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 12.03.2021"],"id":{"eki":["1751234096"],"doi":["10.1007/s10557-010-6231-2"]},"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"20 May 2010"}],"name":{"displayForm":["Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedDisp":"1987-","publisher":"Springer Science + Business Media B.V ; Kluwer","dateIssuedKey":"1987"}],"id":{"issn":["1573-7241"],"eki":["320429237"],"zdb":["2003553-6"]},"disp":"Rationale, design and population baseline characteristics of the PERFORM Vascular Project an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trialCardiovascular drugs and therapy","note":["Gesehen am 05.12.05","Ungezählte Beil.: Suppl"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"320429237","pubHistory":["1.1987/88 -"],"part":{"year":"2010","issue":"2","pages":"175-180","text":"24(2010), 2, Seite 175-180","volume":"24","extent":"6"},"titleAlt":[{"title":"CDT"}],"title":[{"subtitle":"CDT","title":"Cardiovascular drugs and therapy","title_sort":"Cardiovascular drugs and therapy"}]}],"physDesc":[{"extent":"6 S.","noteIll":"Illustrationen"}]} | ||
| SRT | |a HENNERICIMRATIONALED2020 | ||